AstraZeneca has sought leave to file for summary judgement in a U.S. patent dispute with Teva as it tries to stem the threat of generic competition to antipsychotic drug Seroquel.
Teva is challenging patents protecting Seroquel and may offer a less-expensive generic copy of the medicine in the U.S. as early as the end of March, once a 30- month stay on approval is lifted.
WSJ
No comments:
Post a Comment